217 related articles for article (PubMed ID: 32906215)
1. Comprehensive analysis and ACMG-based classification of CHEK2 variants in hereditary cancer patients.
Vargas-Parra G; Del Valle J; Rofes P; Gausachs M; Stradella A; Moreno-Cabrera JM; Velasco A; Tornero E; Menéndez M; Muñoz X; Iglesias S; López-Doriga A; Azuara D; Campos O; Cuesta R; Darder E; de Cid R; González S; Teulé A; Navarro M; Brunet J; Capellá G; Pineda M; Feliubadaló L; Lázaro C
Hum Mutat; 2020 Dec; 41(12):2128-2142. PubMed ID: 32906215
[TBL] [Abstract][Full Text] [Related]
2. Systematic Minigene-Based Splicing Analysis and Tentative Clinical Classification of 52 CHEK2 Splice-Site Variants.
Sanoguera-Miralles L; Valenzuela-Palomo A; Bueno-Martínez E; Esteban-Sánchez A; Lorca V; Llinares-Burguet I; García-Álvarez A; Pérez-Segura P; Infante M; Easton DF; Devilee P; Vreeswijk MPG; de la Hoya M; Velasco-Sampedro EA
Clin Chem; 2024 Jan; 70(1):319-338. PubMed ID: 37725924
[TBL] [Abstract][Full Text] [Related]
3. Screening for BRCA1, BRCA2, CHEK2, PALB2, BRIP1, RAD50, and CDH1 mutations in high-risk Finnish BRCA1/2-founder mutation-negative breast and/or ovarian cancer individuals.
Kuusisto KM; Bebel A; Vihinen M; Schleutker J; Sallinen SL
Breast Cancer Res; 2011 Feb; 13(1):R20. PubMed ID: 21356067
[TBL] [Abstract][Full Text] [Related]
4. Germline CHEK2 Gene Mutations in Hereditary Breast Cancer Predisposition - Mutation Types and their Biological and Clinical Relevance.
Kleiblová P; Stolařová L; Křížová K; Lhota F; Hojný J; Zemánková P; Havránek O; Vočka M; Černá M; Lhotová K; Borecká M; Janatová M; Soukupová J; Ševčík J; Zimovjanová M; Kotlas J; Panczak A; Veselá K; Červenková J; Schneiderová M; Burócziová M; Burdová K; Stránecký V; Foretová L; Macháčková E; Tavandzis S; Kmoch S; Macůrek L; Kleibl Z
Klin Onkol; 2019; 32(Supplementum2):36-50. PubMed ID: 31409080
[TBL] [Abstract][Full Text] [Related]
5. Frequency of pathogenic germline mutation in CHEK2, PALB2, MRE11, and RAD50 in patients at high risk for hereditary breast cancer.
Kim H; Cho DY; Choi DH; Oh M; Shin I; Park W; Huh SJ; Nam SJ; Lee JE; Kim SW
Breast Cancer Res Treat; 2017 Jan; 161(1):95-102. PubMed ID: 27783279
[TBL] [Abstract][Full Text] [Related]
6. Pathogenic and likely pathogenic variants in PALB2, CHEK2, and other known breast cancer susceptibility genes among 1054 BRCA-negative Hispanics with breast cancer.
Weitzel JN; Neuhausen SL; Adamson A; Tao S; Ricker C; Maoz A; Rosenblatt M; Nehoray B; Sand S; Steele L; Unzeitig G; Feldman N; Blanco AM; Hu D; Huntsman S; Castillo D; Haiman C; Slavin T; Ziv E
Cancer; 2019 Aug; 125(16):2829-2836. PubMed ID: 31206626
[TBL] [Abstract][Full Text] [Related]
7. Characterization of the c.793-1G > A splicing variant in CHEK2 gene as pathogenic: a case report.
Agiannitopoulos K; Papadopoulou E; Tsaousis GN; Pepe G; Kampouri S; Kocdor MA; Nasioulas G
BMC Med Genet; 2019 Jul; 20(1):131. PubMed ID: 31349801
[TBL] [Abstract][Full Text] [Related]
8. Good performance of the criteria of American College of Medical Genetics and Genomics/Association for Molecular Pathology in prediction of pathogenicity of genetic variants causing thoracic aortic aneurysms and dissections.
Ponińska JK; Bilińska ZT; Truszkowska G; Michalak E; Podgórska A; Stępień-Wojno M; Chmielewski P; Lutyńska A; Płoski R
J Transl Med; 2022 Jan; 20(1):42. PubMed ID: 35078481
[TBL] [Abstract][Full Text] [Related]
9. Adapting ACMG/AMP sequence variant classification guidelines for single-gene copy number variants.
Brandt T; Sack LM; Arjona D; Tan D; Mei H; Cui H; Gao H; Bean LJH; Ankala A; Del Gaudio D; Knight Johnson A; Vincent LM; Reavey C; Lai A; Richard G; Meck JM
Genet Med; 2020 Feb; 22(2):336-344. PubMed ID: 31534211
[TBL] [Abstract][Full Text] [Related]
10. A novel CHEK2 variant identified by next generation sequencing in an Indian family with hereditary breast cancer syndrome.
Bhai P; Saxena R; Kulshrestha S; Verma IC
Cancer Genet; 2019 Jun; 235-236():13-17. PubMed ID: 31296309
[TBL] [Abstract][Full Text] [Related]
11. Functional Analysis Identifies Damaging CHEK2 Missense Variants Associated with Increased Cancer Risk.
Boonen RACM; Wiegant WW; Celosse N; Vroling B; Heijl S; Kote-Jarai Z; Mijuskovic M; Cristea S; Solleveld-Westerink N; van Wezel T; Beerenwinkel N; Eeles R; Devilee P; Vreeswijk MPG; Marra G; van Attikum H
Cancer Res; 2022 Feb; 82(4):615-631. PubMed ID: 34903604
[TBL] [Abstract][Full Text] [Related]
12. Specifications of the ACMG/AMP variant curation guidelines for the analysis of germline CDH1 sequence variants.
Lee K; Krempely K; Roberts ME; Anderson MJ; Carneiro F; Chao E; Dixon K; Figueiredo J; Ghosh R; Huntsman D; Kaurah P; Kesserwan C; Landrith T; Li S; Mensenkamp AR; Oliveira C; Pardo C; Pesaran T; Richardson M; Slavin TP; Spurdle AB; Trapp M; Witkowski L; Yi CS; Zhang L; Plon SE; Schrader KA; Karam R
Hum Mutat; 2018 Nov; 39(11):1553-1568. PubMed ID: 30311375
[TBL] [Abstract][Full Text] [Related]
13. Differences in cancer prevalence among CHEK2 carriers identified via multi-gene panel testing.
Sutcliffe EG; Stettner AR; Miller SA; Solomon SR; Marshall ML; Roberts ME; Susswein LR; Arvai KJ; Klein RT; Murphy PD; Hruska KS
Cancer Genet; 2020 Aug; 246-247():12-17. PubMed ID: 32805687
[TBL] [Abstract][Full Text] [Related]
14. Management of individuals with germline pathogenic/likely pathogenic variants in CHEK2: A clinical practice resource of the American College of Medical Genetics and Genomics (ACMG).
Hanson H; Astiazaran-Symonds E; Amendola LM; Balmaña J; Foulkes WD; James P; Klugman S; Ngeow J; Schmutzler R; Voian N; Wick MJ; Pal T; Tischkowitz M; Stewart DR;
Genet Med; 2023 Oct; 25(10):100870. PubMed ID: 37490054
[TBL] [Abstract][Full Text] [Related]
15. Evaluating the role of CHEK2 p.(Asp438Tyr) allele in inherited breast cancer predisposition.
Kumpula TA; Koivuluoma S; Soikkonen L; Vorimo S; Moilanen J; Winqvist R; Mantere T; Kuismin O; Pylkäs K
Fam Cancer; 2023 Jul; 22(3):291-294. PubMed ID: 36653541
[TBL] [Abstract][Full Text] [Related]
16. Functional characterization of CHEK2 variants in a Saccharomyces cerevisiae system.
Delimitsou A; Fostira F; Kalfakakou D; Apostolou P; Konstantopoulou I; Kroupis C; Papavassiliou AG; Kleibl Z; Stratikos E; Voutsinas GE; Yannoukakos D
Hum Mutat; 2019 May; 40(5):631-648. PubMed ID: 30851065
[TBL] [Abstract][Full Text] [Related]
17. Improving Genetic Testing in Hereditary Cancer by RNA Analysis: Tools to Prioritize Splicing Studies and Challenges in Applying American College of Medical Genetics and Genomics Guidelines.
Rofes P; Menéndez M; González S; Tornero E; Gómez C; Vargas-Parra G; Montes E; Salinas M; Solanes A; Brunet J; Teulé A; Capellá G; Feliubadaló L; Del Valle J; Pineda M; Lázaro C
J Mol Diagn; 2020 Dec; 22(12):1453-1468. PubMed ID: 33011440
[TBL] [Abstract][Full Text] [Related]
18.
Stolarova L; Kleiblova P; Janatova M; Soukupova J; Zemankova P; Macurek L; Kleibl Z
Cells; 2020 Dec; 9(12):. PubMed ID: 33322746
[TBL] [Abstract][Full Text] [Related]
19. Missense mutations (p.H371Y, p.D438Y) in gene CHEK2 are associated with breast cancer risk in women of Balochistan origin.
Baloch AH; Daud S; Raheem N; Luqman M; Ahmad A; Rehman A; Shuja J; Rasheed S; Ali A; Kakar N; Naseeb HK; Mengal MA; Awan MA; Wasim M; Baloch DM; Ahmad J
Mol Biol Rep; 2014 Feb; 41(2):1103-7. PubMed ID: 24390236
[TBL] [Abstract][Full Text] [Related]
20. A Collaborative Effort to Define Classification Criteria for ATM Variants in Hereditary Cancer Patients.
Feliubadaló L; Moles-Fernández A; Santamariña-Pena M; Sánchez AT; López-Novo A; Porras LM; Blanco A; Capellá G; de la Hoya M; Molina IJ; Osorio A; Pineda M; Rueda D; de la Cruz X; Diez O; Ruiz-Ponte C; Gutiérrez-Enríquez S; Vega A; Lázaro C
Clin Chem; 2021 Mar; 67(3):518-533. PubMed ID: 33280026
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
